Pharmaceuticals India

India Hyperuricemia Drugs Market Analysis, 2024–2034

India Hyperuricemia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $54.1 Mn Estimated value
Estimate 2025 $59.6 Mn 2.2% of the global market
Projected 2034 $142.9 Mn 139.7% Adds $83.3 Mn over 9 forecast years
CAGR 2025–2034 10.2% Faster than 40% of 180 Pharmaceuticals markets here
Key players 5
  • India is 2.17% of the global market.
  • In APAC, the largest is China at $206.3 Mn.
  • Fastest growing: India (this report) at 10.2% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$83.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hyperuricemia Drugs Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $54.1 Mn — —
2025 (base) $59.6 Mn +$5.5 Mn —
2026 (forecast) $65.7 Mn +$6.1 Mn +10.2%
2027 (forecast) $72.4 Mn +$6.7 Mn +21.4%
2028 (forecast) $79.8 Mn +$7.4 Mn +33.8%
2029 (forecast) $87.9 Mn +$8.1 Mn +47.5%
2030 (forecast) $96.9 Mn +$9.0 Mn +62.5%
2031 (forecast) $106.8 Mn +$9.9 Mn +79.1%
2032 (forecast) $117.7 Mn +$10.9 Mn +97.4%
2033 (forecast) $129.7 Mn +$12.0 Mn +117.5%
2034 (forecast) $142.9 Mn +$13.2 Mn +139.7%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.75 Bn
  2. North America $1.53 Bn
  3. US $1.07 Bn
  4. APAC $635.4 Mn
  5. Europe $520.2 Mn
  6. Canada $223.6 Mn
  7. China $206.3 Mn
  8. Japan $178.6 Mn
  9. Middle East $126.4 Mn
  10. Latin America $122.7 Mn
  11. Germany $85.2 Mn
  12. UK $77.0 Mn
  13. Brazil $74.9 Mn
  14. France $65.5 Mn
  15. Italy $63.9 Mn
  16. India (this report) $59.6 Mn
  17. Ecuador $56.2 Mn
  18. Saudi Arabia $54.5 Mn
  19. Spain $48.6 Mn
  20. Africa $42.3 Mn
  21. Mexico $40.9 Mn
  22. Australia $37.3 Mn
  23. New Zealand $28.1 Mn
  24. Russia $26.8 Mn
  25. South Africa $20.7 Mn
  26. UAE $14.9 Mn
  27. Egypt $7.5 Mn
  28. Philippines $6.1 Mn
  29. Hong Kong $4.3 Mn
  30. Malaysia $3.9 Mn
  31. Singapore $3.2 Mn
  32. Thailand $3.0 Mn
  33. Kenya $1.6 Mn

The India Hyperuricemia Drugs Market Analysis Executive Summary

Hyperuricemia drugs lower high uric acid in the blood, which can cause gout and kidney stones and is linked to heart and kidney disease.

Key segments of the hyperuricemia Drugs market include drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors and Recombinant Uricase) and indication (Gout, Chronic Kidney Disease and Tumor Lysis Syndrome).

India Hyperuricemia Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the hyperuricemia Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the hyperuricemia Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Hyperuricemia Drugs Market in India

The hyperuricemia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hyperuricemia Drugs Market in India

Hyperuricemia Drugs in India: rules and payment

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hyperuricemia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hyperuricemia Drugs right now, from free public sources.

Latest research 2,548 papers since 2021 (worldwide)

  1. Curcumin-mediated antimicrobial photodynamic therapy attenuates MRSA skin infection in hyperuricemic mice. Free radical biology & medicine, 2026
  2. Neglected chronic tophaceous gout complicated by massive ulceration and destructive polyarticular arthropathy: a case report. Annals of medicine and surgery (2012), 2026
  3. Primary hyperoxaluria type 2 presenting with febuxostat-associated acute tubular injury in a kidney transplant recipient: a case report. Frontiers in immunology, 2026
  4. Fructose-1,6-bisphosphatase deficiency initially diagnosed as acute necrotizing encephalopathy in a child: a case report. BMC pediatrics, 2026
  5. Advancements in therapeutic targets and drug development for hyperuricemia: Mechanisms, progress, and challenges. Experimental and molecular pathology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hyperuricemia Drugs in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 11th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How much research is published on Hyperuricemia Drugs?
PubMed lists 2,548 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Hyperuricemia Drugs in India? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in India

See all
Same topic, other categories

Related on kidney health

See the topic